Expertise in
1
conditions

Janet S. Graham

Glasgow, SCT, GB 
Expertise in
1
conditions
Glasgow, SCT, GB 

Overview

Janet Graham practices practicing medicine in Glasgow, United Kingdom.

Ms. Graham is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Cerebral Hypoxia, and Gallbladder Adenocarcinoma.

She is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

Glasgow, SCT G120XH, United Kingdom
Other Locations
United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomised, Open-label Trial of a Multimodal Intervention (Exercise, Nutrition and Antiinflammatory Medication) Plus Standard Care Versus Standard Care Alone to Prevent/Attenuate Cachexia in Advanced Cancer Patients Undergoing Chemotherapy
A Randomised, Open-label Trial of a Multimodal Intervention (Exercise, Nutrition and Antiinflammatory Medication) Plus Standard Care Versus Standard Care Alone to Prevent/Attenuate Cachexia in Advanced Cancer Patients Undergoing Chemotherapy
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Behavioral, Other, Dietary supplement, Drug
Study Phase: Phase 3
A Phase Ib/II Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment
A Phase Ib/II Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Capecitabine
Study Phase: Phase 3
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
Enrollment Status: Completed
Publish Date: March 29, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy.
A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy.
Enrollment Status: Completed
Publish Date: January 28, 2020
Intervention Type: Other, Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

43 Total Publications

Correction: JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal‑rich.
Correction: JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal‑rich.
Journal: Journal of experimental & clinical cancer research : CR
Published: August 14, 2026

Frequently Asked Questions about Janet S. Graham

Is Janet S. Graham a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Janet S. Graham is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Janet S. Graham participate in research or clinical trials?

Yes. Janet S. Graham has published 43 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Janet S. Graham's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Graham's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile